Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience

Diagnostics

Serge Aho¹  Sylvain Manfredi²  Marianne Latournerie²  François Ghiringhelli³  Claire Tabouret-Viaud⁴  Guillaume Nodari⁴  Romain Popoff⁴  Alexandre Cochet⁴  Jean-Marc Vrigneaud⁴  Jean-Marc Riedinger⁴  Inna Dygai-Cochet⁴  Romaric Loffroy⁵  Olivier Chevallier⁵  Julie Pellegrinelli⁵ 

[1] Department of Epidemiology and Biostatistics, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon, France;Department of Gastroenterology and Hepatology, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon, France;Department of Medical Oncology, Georges François Leclerc Center, 1 Rue Professeur Marion, 21000 Dijon, France;Department of Nuclear Medicine, Georges François Leclerc Center, 1 Rue Professeur Marion, 21000 Dijon, France;Department of Vascular and Interventional Radiology, Image-Guided Therapy Center, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon, France;

关键词: hepatocellular carcinoma;    colorectal cancer;    liver metastases;    cholangiocarcinoma;    radioembolization;    yttrium-90;   

DOI  :  10.3390/diagnostics11010122

来源: DOAJ

【 摘 要 】

Liver tumors are common and may be unamenable to surgery or ablative treatments. Consequently, other treatments have been devised. To assess the safety and efficacy of transarterial radioembolization (TARE) with Yttrium-90 for hepatocellular carcinoma (HCC), liver-dominant hepatic colorectal cancer metastases (mCRC), and cholangiocarcinoma (CCA), performed according to current recommendations, we conducted a single-center retrospective study in 70 patients treated with TARE (HCC, n = 44; mCRC, n = 20; CCA, n = 6). Safety and toxicity were assessed using the National Cancer Institute Common Terminology Criteria. Treatment response was evaluated every 3 months on imaging studies using Response Evaluation Criteria in Solid Tumors (RECIST) or mRECIST criteria. Overall survival and progression-free survival were estimated using the Kaplan-Meier method. The median delivered dose was 1.6 GBq, with SIR-Spheres^® or TheraSphere^® microspheres. TARE-related grade 3 adverse events affected 17.1% of patients. Median follow-up was 32.1 months. Median progression-free survival was 5.6 months and median overall time from TARE to death was 16.1 months and was significantly shorter in men. Progression-free survival was significantly longer in women (HR, 0.49; 95%CI, 0.26–0.90; p = 0.031). Risk of death or progression increased with the number of systemic chemotherapy lines. TARE can be safe and effective in patients with intermediate- or advanced-stage HCC, CCA, or mCRC refractory or intolerant to appropriate treatments.

【 授权许可】

Unknown